The current stock price of BFRG is 1.15 USD. In the past month the price increased by 17.7%. In the past year, price decreased by -57.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 30.89 | 39.30B | ||
| DOCS | DOXIMITY INC-CLASS A | 27.85 | 8.60B | ||
| WAY | WAYSTAR HOLDING CORP | 24.78 | 6.35B | ||
| HTFL | HEARTFLOW INC | N/A | 2.38B | ||
| CERT | CERTARA INC | 18.18 | 1.45B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.34B | ||
| SDGR | SCHRODINGER INC | N/A | 1.31B | ||
| PHR | PHREESIA INC | N/A | 1.21B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.11B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 633.5 | 1.07B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.77 | 923.25M | ||
| HSTM | HEALTHSTREAM INC | 35.37 | 713.56M |
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2023-02-14. The firm is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
BULLFROG AI HOLDINGS INC
325 Ellington Blvd, Unit 317
Gaithersburg MARYLAND US
Employees: 6
Phone: 12406586710
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2023-02-14. The firm is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
The current stock price of BFRG is 1.15 USD. The price increased by 1.77% in the last trading session.
BFRG does not pay a dividend.
BFRG has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
BULLFROG AI HOLDINGS INC (BFRG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BFRG.
ChartMill assigns a technical rating of 2 / 10 to BFRG. When comparing the yearly performance of all stocks, BFRG is a bad performer in the overall market: 89.58% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to BFRG. While BFRG seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months BFRG reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 18.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -250.37% | ||
| ROE | -348.45% | ||
| Debt/Equity | 0.03 |